Table 2.
Outcome of the patients after second-line chemotherapy
| Cases | Response rate | PFS | OS | |
|---|---|---|---|---|
| (%) | (months) | (months) | ||
| TEC/weekly TC | 24 | 38 | 5.5 (2–20) | 13 (3–44) |
| Docetaxel + CPT-11 | 3 | 33 | 4 (0–5) | 6 (4–10) |
| MPA (oral) | 7 | 0 | 1 (0–3) | 5 (2–22) |
| Etoposide (oral) | 6 | 0 | 2 (1–8) | 9 (4–11) |
| Total | 40 | 25 | 3.5 (0–15) | 10 (2–44) |
No significant difference was demonstrated among the four groups (TECm/TCm/TCw, docetaxel + CPT, MPA and Etoposide)
TECm monthly administration of paclitaxel, epirubicin and carboplatin, TCw weekly administration of paclitaxel and carboplatin, TCm monthly administration of paclitaxel and carboplatin, MPA oral daily medroxyprogesterone acetate, Etoposide oral daily Etoposide, PFS progression-free survival, OS overall survival